The stock price of Boryung Co., Ltd. has skyrocketed on 1 September thanks to the news that it's going to pruchase 10 million doses of A/H1N1 influenza vaccine from China's drugmaker Sinovac Biotech Co. Ltd..

Today's opening price of Boryung's share was 14.91%(48,550 won) higher than the previous day's closing quotation(42.250 won).

And the prices of shares of other domestic pharmaceutical companies related to the A/H1N1 influenza vaccines(ex. Green Cross) have also risen.

Boryung plans to supply the A/H1N1 influenza vaccine to the domestic market through its subsidiary company,'Boryeong Bio Pharma'.

An offlcal of Boryung said, "As for the quantity of supply of the new flu vaccine, we are going to discuss with the Korea Centers for Disease Control and Prevention(KCDC). And more than 10 million doses will be supplied."

He also explained, "As the preventive effectiveness of Sinovac's A/H1N1 influenza vaccine was proved with a single vaccination in clinical trials, 10 million people could be vaccinated with 10 million doses."

The Korean government has announced that in preparation of the potential spreading of the A/H1N1 influenza, it would vaccinate 27 % of the population, or over 13 million people until February 2010.

A total of 1,796 A/H1N1 influenza patients are currently undergoing treatment as of 31 August. [헬스코리아뉴스]

▶ 보령제약 “중국산 신종플루 백신 국내 독점계약”

Healthkoreanews 다른기사 보기